Search Results - "Jimeno, J. M"

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia by Guisado-Vasco, P, Carralón-González, M M, Aguareles-Gorines, J, Martí-Ballesteros, E M, Sánchez-Manzano, M D, Carnevali-Ruiz, D, García-Coca, M, Barrena-Puertas, R, de Viedma, R García, Luque-Pinilla, J M, Sotres-Fernandez, G, Fernández-Sousa, J M, Luepke-Estefan, X E, López-Martín, J A, Jimeno, J M

“…There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern…”
Get full text

Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors by TAAMMA, A, MISSET, J. L, RIOFRIO, M, GUZMAN, C, BRAIN, E, LOPEZ LAZARO, L, ROSING, H, JIMENO, J. M, CVITKOVIC, E

“…To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3…”
Get full text

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer by Hendriks, H. R., Fiebig, H. H., Giavazzi, R., Langdon, S. P., Jimeno, J. M., Faircloth, G. T.

“…Background: Ecteinascidin-743 (ET743) is a novel antitumour agent originating from the Caribbean tunicate Ecteinascidia turbinata. It has potent cytotoxic and…”
Get full text

Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin by van Kesteren, Ch, de Vooght, M. M. M, López-Lázaro, L, Mathôt, R. A. A, Schellens, J. H. M, Jimeno, J. M, Beijnen, J. H

“…Yondelis (trabectedin, ET-743) is a novel antitumor agent derived from a marine source, the Caribbean tunicate Ecteinascidia turbinata. Preclinical studies…”
Get full text

Pocket ultrasound device, PM & rehabilitation physician's stethoscope by de Miguel-Jimeno, J M, Zabalza-Azparren, M

Get more information

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry by Stokvis, E., Rosing, H., López-Lázaro, L., Rodriguez, I., Jimeno, J. M., Supko, J. G., Schellens, J. H. M., Beijnen, J. H.

“…Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human…”
Get full text

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy by Guisado-Vasco, P., González-Cortijo, L., D'Errico, G., Serrera-Alvarez, A., Sotres-Fernandez, G., García-Coca, M., Fernández-Sousa, J.M., Luepke-Estefan, X.E., López-Martín, J.A., Jimeno, J.M.

Get full text

PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors by Karp, D D, Camidge, D R, Infante, J R, Ames, T D, Jimeno, J M, Bryce, A H

Get full text

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study by VAN KESTEREN, Charlotte, CVITKOVIC, Esteban, HILLEBRAND, Michael J. X, ROSING, Hilde, BEIJNEN, Jos H, TAAMMA, Adelkrim, LOPEZ-LAZARO, Luis, JIMENO, Jose M, GUZMAN, Cecilia, MATHOT, Ron A. A, SCHELLENS, Jan H. M, MISSET, Jean-Louis, BRAIN, Etienne

“…Ecteinascidin (ET) 743 is an anticancer agent derived from the Caribbean tunicate Ecteinascidia turbinata . Preclinical studies revealed activity of ET-743…”
Get full text

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients by Huygh, G, Clement, Paul M J, Dumez, H, Schöffski, P, Wildiers, H, Selleslach, J, Jimeno, J M, Wever, I De, Sciot, R, Duck, L, Van Oosterom, A T

“…Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma…”
Get full text

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry by Rosing, H., Hillebrand, M. J. X., Jimeno, J. M., Gómez, A., Floriano, P., Faircloth, G., Henrar, R. E. C., Vermorken, J. B., Cvitkovic, E., Bult, A., Beijnen, J. H.

“…A method was developed for the bio‐analysis of Ecteinascidin 743 (ET‐743) using miniaturized liquid chromatography (LC) coupled to an electrospray ionization…”
Get full text

Pharmaceutical development of anticancer agents derived from marine sources by Nuijen, B, Bouma, M, Manada, C, Jimeno, J M, Schellens, J HM, Bult, A, Beijnen, J H

“…The marine ecosystem is more and more acknowledged as a source of potential anticancer agents. After the identification of a potential substance several…”
Get full text

Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity by Luber-Narod, J, Smith, B, Grant, W, Jimeno, J.M, López-Lázaro, L, Faircloth, G.T

“…Our laboratory has begun work on an in vitro screening system designed to determine which experimental drugs are most likely to be safe candidates for…”
Get full text

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F by Nuijen, Bastiaan, Nuijen, B., Bouma, M., Talsma, H., Manada, C., Jimeno, J. M., Lopez-Lazaro, L., Bult, A., Beijnen, J. H.

“…Kahalalide F is a novel antitumor agent isolated from the marine mollusk Elysia rufescens; it has shown highly selective in vitro activity against…”
Get full text

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion by VAN KESTEREN, Charlotte, MATHOT, R. A. A, HILLEBRAND, M. J. X, ROSING, H, BEIJNEN, J. H, LOPEZ-LAZARO, L, CVITKOVIC, E, TAAMMA, A, JIMENO, J. M, GUZMAN, C, SCHELLENS, J. H. M, MISSET, J. L, BRAIN, E

“…Ecteinascidin 743 (ET-743) is a novel, marine-derived anticancer agent currently under clinical development for the treatment of solid tumors. The aim of this…”
Get full text

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine by Nuijen, B, Bouma, M, Henrar, R E, Floriano, P, Jimeno, J M, Talsma, H, Kettenes-van den Bosch, J J, Heck, A J, Bult, A, Beijnen, J H

“…Aplidine is a naturally occurring cyclic depsipeptide isolated from the Mediterranean tunicate Aplidium albicans. Aplidine displays promising in vitro and in…”
Get more information

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol by Nuijen, B, Bouma, M, Manada, C, Jimeno, J M, Bult, A, Beijnen, J H

“…An in vitro biocompatibility study was performed with the pharmaceutical formulation of the investigational, marine-derived anticancer agent kahalalide F…”
Get more information

Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate by Quesada, A R, Jimeno, J M, Márquez, G, Aracil, M

“…Clinical studies have shown that continuous or intermittent scheduled administration of medroxyprogesterone acetate (MPA) reduces the bone marrow toxicity…”
Get more information

A clinical armamentarium of marine-derived anti-cancer compounds by Jimeno, José M

“…The sea, covering 70% of the Earthʼs surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of…”
Get full text

437PPT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors by Karp, D D, Camidge, D R, Infante, J R, Ames, T D, Jimeno, J M, Bryce, A H

Get full text